AU8539398A - Treatment of diabetes with thiazolidinedione and metformin - Google Patents

Treatment of diabetes with thiazolidinedione and metformin Download PDF

Info

Publication number
AU8539398A
AU8539398A AU85393/98A AU8539398A AU8539398A AU 8539398 A AU8539398 A AU 8539398A AU 85393/98 A AU85393/98 A AU 85393/98A AU 8539398 A AU8539398 A AU 8539398A AU 8539398 A AU8539398 A AU 8539398A
Authority
AU
Australia
Prior art keywords
compound
administration
pharmaceutically acceptable
thiazolidine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU85393/98A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU8539398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to AU10119/02A priority Critical patent/AU778947B2/en
Publication of AU8539398A publication Critical patent/AU8539398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU85393/98A 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin Abandoned AU8539398A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10119/02A AU778947B2 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GB9712857 1997-06-18
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
GB9806706 1998-03-27
PCT/EP1998/003690 WO1998057634A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU10119/02A Division AU778947B2 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Publications (1)

Publication Number Publication Date
AU8539398A true AU8539398A (en) 1999-01-04

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85393/98A Abandoned AU8539398A (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Country Status (38)

Country Link
US (3) US20060100247A1 (en:Method)
EP (2) EP0996444B1 (en:Method)
JP (1) JP2002504137A (en:Method)
KR (2) KR100666591B1 (en:Method)
CN (2) CN1230171C (en:Method)
AP (1) AP1279A (en:Method)
AR (2) AR012995A1 (en:Method)
AT (1) ATE355840T1 (en:Method)
AU (1) AU8539398A (en:Method)
BG (2) BG64818B1 (en:Method)
BR (1) BR9810172A (en:Method)
CA (1) CA2294582C (en:Method)
CY (2) CY1107643T1 (en:Method)
CZ (1) CZ298469B6 (en:Method)
DE (2) DE122007000054I1 (en:Method)
DK (1) DK0996444T3 (en:Method)
DZ (1) DZ2520A1 (en:Method)
EA (1) EA003144B1 (en:Method)
ES (1) ES2284212T3 (en:Method)
ID (1) ID23372A (en:Method)
IL (3) IL133142A0 (en:Method)
IN (1) IN189722B (en:Method)
LU (1) LU91356I2 (en:Method)
MA (1) MA26512A1 (en:Method)
MY (1) MY129897A (en:Method)
NL (1) NL300288I2 (en:Method)
NO (4) NO324993B1 (en:Method)
NZ (1) NZ501260A (en:Method)
OA (1) OA11516A (en:Method)
PE (1) PE83199A1 (en:Method)
PL (2) PL195136B1 (en:Method)
PT (1) PT996444E (en:Method)
SI (1) SI0996444T1 (en:Method)
SK (1) SK286029B6 (en:Method)
TR (1) TR199903057T2 (en:Method)
TW (1) TW565449B (en:Method)
UY (1) UY25049A1 (en:Method)
WO (1) WO1998057634A1 (en:Method)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
SI0974356T1 (en) * 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AP1495A (en) 1999-04-23 2005-11-30 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic.
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
BR0015294A (pt) 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
ATE508738T1 (de) 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
JP4694841B2 (ja) * 2002-09-20 2011-06-08 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
PL377403A1 (pl) 2003-01-29 2006-02-06 Takeda Pharmaceutical Company Limited Sposób wytwarzania preparatu powlekanego
JP4739189B2 (ja) 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
EP1772149A1 (en) * 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
EP1905450A1 (en) * 2005-07-12 2008-04-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar gamma agonist
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
WO2010012650A1 (en) * 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
JP2015503582A (ja) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
PT832066E (pt) * 1995-06-06 2001-12-28 Pfizer N-substituido-(indole-2-carbonil)-amidas e derivados como inibidores de glicogenio-fosforilase
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
AR012998A1 (es) 2000-11-22
KR20010013844A (ko) 2001-02-26
WO1998057634A1 (en) 1998-12-23
CY2007018I1 (el) 2012-01-25
NO324993B1 (no) 2008-01-14
PE83199A1 (es) 1999-10-22
IL133142A0 (en) 2001-03-19
SK286029B6 (sk) 2008-01-07
NO2008003I1 (no) 2008-04-21
JP2002504137A (ja) 2002-02-05
EA200000041A1 (ru) 2000-08-28
CN1260716A (zh) 2000-07-19
AP1279A (en) 2004-05-20
PL337362A1 (en) 2000-08-14
US20080090881A1 (en) 2008-04-17
NO2008003I2 (no) 2010-06-28
PT996444E (pt) 2007-06-08
NL300288I2 (nl) 2009-06-02
IL173650A0 (en) 2006-07-05
CN1114404C (zh) 2003-07-16
NL300288I1 (nl) 2007-11-01
BG104060A (en) 2000-10-31
CZ9904578A3 (en) 2001-06-13
EP1787646A3 (en) 2007-10-03
PL195140B1 (pl) 2007-08-31
CZ298469B6 (cs) 2007-10-10
IN189722B (en:Method) 2003-04-19
EP1787646A2 (en) 2007-05-23
ES2284212T3 (es) 2007-11-01
NO996266L (no) 1999-12-17
NO996266D0 (no) 1999-12-17
CA2294582A1 (en) 1998-12-23
OA11516A (en) 2004-02-04
NZ501260A (en) 2002-09-27
MA26512A1 (fr) 2004-12-20
DE122007000054I1 (de) 2007-12-13
CN1429551A (zh) 2003-07-16
DE69837261D1 (de) 2007-04-19
CA2294582C (en) 2008-02-12
BR9810172A (pt) 2000-08-08
EP0996444A1 (en) 2000-05-03
EP0996444B1 (en) 2007-03-07
HK1028193A1 (en) 2001-02-09
TW565449B (en) 2003-12-11
ATE355840T1 (de) 2007-03-15
PL195136B1 (pl) 2007-08-31
CY1107643T1 (el) 2012-01-25
LU91356I2 (fr) 2008-01-29
KR20060105005A (ko) 2006-10-09
DZ2520A1 (fr) 2003-02-01
SI0996444T1 (sl) 2007-08-31
TR199903057T2 (xx) 2000-04-21
ID23372A (id) 2000-04-20
NO20090846L (no) 1999-12-17
MY129897A (en) 2007-05-31
DK0996444T3 (da) 2007-07-02
BG109398A (bg) 2006-05-31
CN1230171C (zh) 2005-12-07
US20070004780A1 (en) 2007-01-04
BG64818B1 (bg) 2006-05-31
SK179299A3 (en) 2000-11-07
IL133142A (en) 2006-06-11
US20060100247A1 (en) 2006-05-11
DE69837261T2 (de) 2007-11-08
KR100666591B1 (ko) 2007-01-11
NO326958B1 (no) 2009-03-23
NO20063000L (no) 1999-12-17
AP9901719A0 (en) 1999-12-31
EA003144B1 (ru) 2003-02-27
AR012995A1 (es) 2000-11-22
UY25049A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
AP1279A (en) Treatment of diabetes with thiazolidinedione and metformin.
US20020137772A1 (en) Treatment of diabetes with thiazolidinedione and metformin
EP1001783B1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20040097556A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU8799998A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
WO1999003478A1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
AU8539298A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
HK1107015A (en) Method of treatment of diabetes with a combination of a thiazolidinedione and metformin
US20020123514A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
CA2549864A1 (en) Treatment of diabetes with thiazolidinedione and metformin
NZ515554A (en) Treatment of diabetes with thiazolidinedione and metformin
HK1028193B (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012078A (en) Treatment of diabetes with thiazolidinedione and metformin
AU1540002A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1091393A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted